Drugs / serrapeptase
serrapeptase
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT07304882 | Nov 2023 → Jan 2025 | impacted teeth, multiple | University of Science and Technology, Yemen | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07543146 | Jun → Sep 2025 | — | Sharif Medical Research Center | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT07146997 Comparator | Nov 2023 → Nov 2024 | pulpitis | Zahoor khan | Completed | No outcome recorded |
| — | NCT03177889 Background | Dec 2021 → Aug 2023 | bronchiectasis | Guangzhou Institute of Respiratory Disease | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | serrapeptase | “oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid]” NCT03177889 ↗ |
| Known as | Aniflazym | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108880 ↗ |
| Known as | Irzaim | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108880 ↗ |
| Known as | Serralysin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108880 ↗ |
| Known as | Serrapeptasa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108880 ↗ |
| Known as | serratiopeptidase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07304882 ↗ |
| Action | Inhibit | “possibly inhibiting prostaglandin production” NCT07146997 ↗ |
| Modality | Protein / enzyme biologic | “Serratiopeptidase is a proteolytic enzyme” NCT07146997 ↗ |
| Route | Oral | “oral mucolytics” NCT03177889 ↗ |